publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
c
adult
dose
children
yr
age
pediatr
dose
mg
children
yr
age
maximum
recommend
dosag
older
adult
yr
mgday
recommend
pediatr
dosag
mgkgday
maximum
mgday
divid
dose
prophylaxi
daili
dosag
given
period
risk
e
pediatr
dosag
mgkg
maximum
mgday
divid
dose
approv
fda
treatment
children
yr
age
prophylaxi
daili
dosag
given
period
risk
f
reservoir
concentr
mgml
special
aerosolgener
devic
avail
manufactur
expert
respiratori
therapi
monitor
administr
requir
higher
reservoir
concentr
mgml
given
hr
tid
altern
note
pleas
consult
text
manufactur
product
prescrib
inform
dosag
adjust
renal
hepat
insuffici
circumst
chapter
antivir
agent
influenza
virus
certain
respiratori
virus
parainfluenza
respiratori
syn
cytial
viru
review
tabl
antivir
agent
pre
sent
alphabet
order
includ
licens
approv
well
investig
agent
agent
investig
rhino
viru
infect
util
primarili
nonrespiratori
tract
infect
interferon
pleconaril
discuss
chapter
amantadin
hydrochlorid
symmetrel
rimantadin
methylamin
hydrochlorid
flumadin
symmetr
tricycl
amin
fig
b
specif
inhibit
replic
influenza
virus
low
con
centrat
influenza
b
c
virus
resist
past
epidem
human
avian
strain
influenza
virus
gener
suscept
amantadin
howev
sinc
isol
influenza
highli
pathogen
avian
resist
amantadin
rimantadin
see
later
discuss
plaqu
assay
inhibitori
con
centrat
drug
rang
less
sensi
tive
human
influenza
virus
rimantadin
time
activ
amantadin
assay
system
drug
inhibi
tori
viru
contain
protein
pandem
strain
higher
concentr
inhibit
envelop
virus
vitro
includ
parainfluenza
influenza
b
rubella
dengu
sever
arenavirus
junin
lassa
pichind
rabi
african
swine
fever
viru
concentr
achiev
clinic
cytotox
vitro
rimantadin
phdepend
trypanocid
activ
concentr
approxim
amantadin
concentr
combin
doxyci
cline
inhibit
coxiella
burnetii
amantadin
may
transient
inhibit
hepat
c
viru
hcv
replic
human
agent
prophylact
therapeut
activ
experi
mental
influenza
viru
infect
anim
oral
parenter
dose
combin
inhibitor
neuraminidas
inhibitor
ribavirin
show
enhanc
antivir
therapeut
effect
vitro
anim
model
influenza
amantadin
rimantadin
share
two
concentrationdepend
mechan
antiinfluenza
action
low
concentr
inhibit
ion
channel
function
protein
influenza
virus
affect
two
differ
stage
viru
replic
primari
effect
involv
inhibit
viral
uncoat
disassembl
virion
endocytosi
subtyp
virus
late
effect
hemagglutinin
matur
viral
assembl
presum
mediat
alter
ph
regul
transgolgi
network
amantadin
rimantadin
block
proton
permeat
prevent
chang
ph
action
probabl
account
inhibit
acidmedi
dissoci
matrix
protein
ribonucleo
protein
complex
within
endosom
earli
replic
potentia
tion
acid
phinduc
alter
hemagglutinin
transport
late
infect
amantadin
rimantadin
also
concentr
lyso
somal
fraction
mammalian
cell
drugmedi
increas
lyso
somal
ph
may
inhibit
virusinduc
membran
fusion
event
account
broader
antivir
spectrum
higher
concentr
contrast
select
antiinfluenza
viru
effect
quickli
lost
remov
drug
surround
medium
oral
administ
oseltamivir
effect
prevent
treatment
uncompl
influenza
otherwis
healthi
adult
observ
studi
suggest
benefici
seriou
ill
toxic
primarili
gastrointestin
administr
oral
inhal
powder
effect
similar
oseltamivir
activ
oseltamivirresist
strain
bronchospasm
may
occur
individu
asthma
chronic
obstruct
pulmonari
diseas
widespread
resist
agent
present
current
circul
influenza
virus
use
unless
sensit
isol
demonstr
oral
administ
shown
efficaci
uncompl
influenza
effect
seriou
ill
establish
toxic
amantadin
primarili
evid
central
nervou
system
symptom
rimantadin
gastrointestin
intoler
peramivir
intraven
administr
neuraminidas
inhibitor
laninamivir
oral
inhal
neuraminidas
inhibitor
prolong
presenc
respiratori
tract
guanosin
analogu
ribavirin
activ
broad
varieti
virus
includ
respiratori
syncyti
viru
rsv
influenza
approv
aerosol
administr
children
hospit
rsv
pneumonia
bronchiol
use
treat
viral
respiratori
tract
infect
immunosuppress
patient
teratogen
use
near
potenti
pregnant
staff
investig
agent
inhibit
rsv
interact
nucleocapsid
protein
well
absorb
oral
phase
ii
studi
underway
investig
compound
activ
parainfluenza
influenza
virus
oral
inhal
sialidas
reduc
viru
bind
epitheli
cell
use
treat
parainfluenza
viru
type
infect
immunosuppress
patient
approxim
drugtreat
ambulatori
children
adult
hospit
children
immunocompromis
patient
shed
resist
viru
immunocompet
individu
shed
resist
viru
resolv
ill
promptli
wherea
immunocompromis
host
may
experi
enc
prolong
ill
associ
persist
viru
shed
transmiss
inhibitorresist
viru
associ
failur
drug
prophylaxi
occur
household
contact
treat
index
case
nurs
home
resid
resist
variant
caus
typic
influenza
ill
prudent
avoid
contact
treat
patient
suscept
highrisk
contact
avoid
use
treat
ment
specif
young
children
postexposur
prophylaxi
household
global
epidem
influenza
strain
inhibitor
sensit
sinc
preval
amantadin
resist
increas
progress
although
rate
vari
viru
type
geographi
among
isol
amantadin
resist
increas
worldwid
greater
unit
state
prior
march
nearli
isol
test
sensit
adaman
tane
subsequ
virtual
isol
resi
tant
present
includ
viru
among
nonpandem
isol
preval
amantadin
resist
worldwid
isol
rate
rang
south
korea
china
reason
emerg
global
spread
amantadineresist
strain
unclear
widespread
inappropri
use
amantadin
acquisit
undefin
advantag
mutat
combin
lack
fit
impair
may
contribut
factor
ribavirin
neuraminidas
inhibitor
zanamivir
oseltamivir
carboxyl
ate
activ
vitro
inhibitorresist
strain
tripl
combin
amantadin
oseltamivir
ribavirin
imped
select
drugresist
influenza
viru
vitro
clinic
achiev
concentr
compar
doubl
combina
tion
agent
use
singli
vitro
combin
drug
also
synergist
vitro
inhibit
growth
amantadin
oseltamivirresist
influenza
viru
strain
con
centrat
activ
singl
agent
clinic
pharmacokinet
characterist
amantadin
riman
tadin
shown
tabl
amantadin
well
absorb
oral
administr
capsul
tablet
syrup
form
steadyst
peak
plasma
concentr
averag
twicedaili
regimen
healthi
young
adult
older
adult
requir
one
half
weightadjust
dosag
need
young
adult
achiev
equival
trough
plasma
level
plasma
protein
bind
amantadin
amantadin
volum
distribut
v
larg
l
kg
nasal
secret
salivari
level
amantadin
approxim
found
serum
cerebrospin
fluid
level
plasma
amantadin
excret
breast
milk
amantadin
elimin
larg
unchang
urin
glo
merular
filtrat
probabl
tubular
secret
bicarbon
depend
organ
cation
transport
plasma
elimin
halflif
elim
hour
rang
wide
correl
creatinin
clearanc
crcl
agerel
declin
renal
function
elim
increas
twofold
older
adult
even
patient
impair
renal
function
dosag
reduct
requir
renal
insuffici
tabl
amantadin
ineffici
clear
patient
receiv
hemodialysi
continu
ambulatori
perito
neal
dialysi
addit
dose
requir
monitor
plasma
concentr
patient
desir
impract
amantadin
pharmacokinet
remain
unaffect
concurr
administr
oseltamivir
ribavirin
healthi
adult
volunt
stabl
immunocompromis
patient
suggest
drug
must
present
extracellular
fluid
earli
replic
cycl
amantadin
inhibit
ion
channel
activ
express
hcv
protein
low
concentr
effect
might
account
report
antihcv
effect
vivo
neither
agent
inhibit
hcv
enzym
function
intern
ribosom
entri
biochem
assay
resist
amantadineresist
viru
readili
select
viru
passag
presenc
drug
resist
increas
inhibitori
concentr
associ
singl
aminoacid
substitut
critic
site
posit
transmembran
region
protein
amantadin
rimantadin
share
crossresist
avian
model
resist
virus
virul
genet
stabl
abl
compet
wildtyp
viru
mgkg
day
peak
serum
level
rang
import
agerel
chang
pharmacokinet
found
healthi
older
adult
children
howev
steadyst
plasma
concentr
older
nurs
home
resid
receiv
mg
twice
daili
averag
twofold
higher
mean
ml
concentr
observ
healthi
adult
indic
need
lower
dosag
patient
plasma
protein
bind
rimantadin
larg
v
lkg
concentra
tion
nasal
mucu
averag
higher
plasma
contrast
amantadin
rimantadin
undergo
extens
metabol
hydroxyl
conjug
glucuronid
renal
excret
plasma
elim
rimantadin
averag
hour
clinic
import
differ
pharmacokinet
found
patient
chronic
liver
diseas
without
signific
hepa
tocellular
dysfunct
hemodialysi
patient
sever
renal
failur
clearanc
rimantadin
decreas
elim
longer
reduc
dosag
one
half
eg
mg
day
recommend
mark
hepat
renal
insuffici
crcl
mlmin
hemodialysi
remov
small
amount
riman
tadin
supplement
dose
requir
risk
central
nervou
system
cn
advers
effect
amantadin
possibl
rimantadin
increas
concomi
tant
ingest
antihistamin
antidepress
anticholinerg
drug
drug
affect
cn
function
concurr
use
trimethoprimsulfamethoxazol
triamterenehydrochlorothiazid
associ
cn
toxic
result
decreas
renal
clearanc
amantadin
cimetidin
associ
increas
aspirin
acetaminophen
associ
decreas
plasma
rimantadin
concentr
chang
unlik
signific
neither
advers
clinic
advers
pharma
cokinet
effect
observ
amantadin
oseltamivir
coadminist
concurr
administr
recommend
dose
amantadin
oseltamivir
ribavirin
day
well
toler
amantadin
rimantadin
given
treatment
cours
day
gener
well
toler
young
healthi
adult
longer
period
administr
week
season
prophylaxi
young
adult
administr
fragil
elderli
nurs
home
resid
octogenarian
day
outbreak
control
associ
signific
frequenc
advers
reaction
drug
withdraw
casecontrol
studi
demonstr
children
younger
month
age
amantadin
rimantadin
well
toler
oseltamivir
evid
advers
matern
neonat
come
observ
antepartum
influenza
treatment
ada
mantan
antivir
agent
common
side
effect
relat
amantadin
ingest
minor
doserel
gastrointestin
cn
complaint
includ
nervous
lightheaded
difficulti
concentr
confus
insomnia
loss
appetit
nausea
complaint
typic
develop
within
first
week
administr
often
resolv
despit
continu
ingest
revers
drug
discontinu
cn
side
effect
occur
amantadin
recipi
dosag
mgday
significantli
less
frequent
rimantadin
use
influenza
prophylaxi
ambulatori
adult
dosag
mgday
associ
excess
withdraw
recipi
drug
side
effect
dosag
mgday
better
toler
may
protect
influenza
ill
amantadin
dosag
reduc
tion
requir
older
adult
mgday
nurs
home
resid
experi
signific
advers
effect
lower
dosag
despit
adjust
renal
insuffici
con
sequent
dosag
reduct
base
crcl
warrant
popul
set
renal
insuffici
high
dosag
seriou
neuro
toxic
reaction
includ
delirium
hostil
hallucin
tremor
myoclonu
seizur
coma
cardiac
arrhythmia
death
occur
associ
elev
amantadin
plasma
concentr
rimantadin
well
slowli
absorb
time
peak
plasma
concentr
averag
hour
absorpt
seem
decreas
food
multipl
dose
mg
twice
daili
steadyst
peak
trough
plasma
concentr
healthi
adult
infant
receiv
dosag
amantadin
rimantadin
also
effect
therapi
un
complic
adamantanesuscept
influenza
ill
healthi
adult
uncertain
whether
treatment
reduc
risk
complic
highrisk
patient
use
patient
estab
lish
pulmonari
complic
earli
treatment
ambulatori
adult
mgday
day
reduc
durat
fever
system
complaint
day
decreas
viru
shed
shorten
time
resumpt
usual
activ
ill
caus
influenza
virus
certain
abnorm
peripher
airway
function
airway
hyperreact
resolv
quickli
amantadin
treat
patient
amantadin
rimantadin
treatment
adult
leukemia
stem
cell
transplant
may
reduc
risk
pneumo
nia
recent
data
suggest
stem
cell
transplant
recipi
ent
earli
neuraminidas
inhibitor
therapi
may
prefer
adamantan
may
prevent
progress
pneumonia
decreas
viral
shed
therebi
possibl
prevent
influenza
relat
death
index
patient
nosocomi
transmiss
other
children
rimantadin
treatment
associ
lower
symptom
burden
fever
viral
titer
first
day
treatment
com
pare
acetaminophen
administr
rimantadinetr
children
prolong
shed
viru
treatment
gener
seem
affect
humor
immun
respons
infect
may
blunt
secretori
antibodi
level
intermitt
aerosol
administr
amantadin
rimantadin
seem
therapeut
use
uncompl
influenza
inject
formul
either
drug
avail
unit
state
amantadin
use
multipl
trial
treatment
chronic
hepat
c
inconsist
evid
increas
sustain
viral
respons
svr
patient
addit
amanta
dine
mg
daili
singl
divid
dose
interferon
interferon
plu
ribavirin
may
modestli
increas
biochem
respons
likelihood
svr
retreat
interferon
nonrespond
combin
interferon
plu
amantadin
inef
fectiv
addit
amantadin
combin
inter
feron
plu
ribavirin
may
associ
svr
amantadin
plu
combin
pegyl
interferon
ribavirin
may
increas
svr
modestli
treatmentexperienc
patient
compar
pegyl
interferon
plu
ribavirin
report
possibl
activ
bornaviru
infect
associ
neuropsychiatr
symptom
requir
confirm
investig
antivir
agent
activ
influ
enza
b
virus
parainfluenza
virus
type
novel
mechan
action
sialidas
actinomyc
viscosu
fig
link
respiratori
epitheliumanchor
domain
cleav
termin
sialic
acid
residu
surfac
human
respiratori
cell
thu
reduc
bind
respiratori
virus
use
receptor
desialyl
rapid
result
antivir
effect
last
least
day
effect
concentr
ec
isol
ec
influenza
b
virus
rang
activ
influenza
virus
resist
neuraminidas
inhibitor
low
level
resist
induc
resist
variant
appear
reduc
fit
administ
oral
inhal
appear
gener
alli
well
toler
phase
ii
placebocontrol
studi
recent
conduct
subject
influenza
b
viru
infect
administ
either
singl
dose
daili
dose
day
compar
placebo
recipi
recipi
statist
signific
decreas
viru
load
deter
mine
polymeras
chain
reaction
pcr
assay
day
day
howev
differ
resolut
clinic
ill
among
group
administr
appear
gener
well
toler
although
transient
elev
alkalin
phosphatas
level
report
also
util
treat
parainfluenza
viru
type
infect
lung
transplant
stem
cell
transplant
patient
case
report
describ
clinic
improv
increas
pulmonari
neurotox
reaction
may
transient
revers
physostigmin
administr
lidocain
use
treat
ventricular
arrhythmia
longterm
amantadin
ingest
associ
livedo
reticulari
peripher
edema
orthostat
hypo
tension
rare
congest
heart
failur
vision
loss
urinari
retent
peripher
edema
livedo
reticulari
may
improv
treatment
switch
amantadin
rimantadin
patient
preexist
seizur
disord
increas
frequenc
major
motor
seizur
amantadin
use
dosag
reduct
advis
psychiatr
side
effect
patient
parkinson
diseas
psychot
exacerb
patient
schizophrenia
may
occur
addit
amantadin
rash
leukopenia
describ
rare
rimantadin
administr
associ
doserel
side
effect
similar
side
effect
observ
amantadin
although
risk
cn
side
effect
lower
rimantadin
dosag
mgday
mgday
ambulatori
adult
prophylaxi
excess
withdraw
rate
usual
less
older
nurs
home
resid
dosag
mgday
associ
higher
side
effect
rate
wherea
dosag
mgday
seem
better
toler
rimantadin
may
uncommonli
caus
exacerb
seizur
patient
receiv
anticonvuls
associ
unexplain
excess
mortal
one
nurs
home
studi
clinic
observ
dri
mouth
pupillari
dilat
toxic
psychosi
urinari
retent
acut
amantadin
overdos
suggest
anticholinerg
activ
present
human
amantadin
show
activ
adrenerg
nervou
system
affect
accumul
releas
reuptak
catecholamin
cn
periph
eral
nervou
system
malign
ventricular
arrhythmia
amanta
dine
overdos
describ
human
amantadin
rimantadin
lack
mutagen
vitro
carcino
genic
studi
report
either
amantadin
tera
togen
embryotox
rat
rimantadin
may
caus
teratogen
effect
rabbit
matern
toxic
embryotox
high
dosag
rodent
drug
classifi
pregnanc
categori
c
birth
defect
report
amantadin
exposur
pregnanc
safeti
neither
amantadin
rimantadin
establish
pregnanc
excret
breast
milk
use
recommend
nurs
mother
amantadin
rimantadin
efficaci
prevent
treatment
influenza
viru
infect
young
healthi
adult
systemat
review
publish
studi
children
elderli
conclud
avail
data
demonstr
aman
tadin
prophylact
efficaci
modest
therapeut
effect
children
elderli
data
avail
support
conclu
sion
prophylact
therapeut
efficaci
either
adamantan
emerg
widespread
nearli
complet
amantadin
resist
among
influenza
isol
well
amantadin
resi
tanc
pandem
strain
preclud
empiri
cal
use
adamantan
manag
untyp
influenza
outbreak
amantadin
rimantadin
dosag
mg
day
adult
protect
clinic
ill
caus
variou
suscept
influenza
subtyp
includ
suscep
tibl
pandem
strain
prophylaxi
effect
prevent
nosoco
mial
influenza
possibl
curtail
nosocomi
outbreak
caus
strain
protect
seem
addit
provid
vaccin
rimantadin
less
effect
zanamivir
reduc
case
influenza
ill
adult
longterm
care
facil
differ
protect
efficaci
larg
due
emerg
rimantadin
resist
virus
caus
rimantadin
prophylact
failur
zanamivirresist
virus
isol
rimantadin
administr
schoolag
children
mgkgday
decreas
risk
influenza
ill
recipi
possibl
famili
contact
postexpo
sure
prophylaxi
drug
provid
inconsist
protect
famili
contact
howev
part
depend
whether
ill
index
chil
dren
treat
dosag
mgday
seem
protect
influenza
ill
well
toler
adult
spectrum
laninamivir
octano
exhibit
littl
influenza
viru
neuramini
dase
inhibitori
activ
vitro
howev
hydrolysi
product
potent
inhibitor
neuraminidas
influenza
virus
plu
influenza
b
replic
cell
cultur
nanomolar
concentr
includ
season
pandem
influenza
highli
pathogen
avian
influenza
hpai
virus
clinic
isol
oseltamivirresist
median
inhibitori
concentr
cell
cultur
vari
wide
rang
gener
appear
intermedi
oseltamivir
carboxyl
lower
zanamivir
higher
clinic
import
differ
yet
known
preclin
studi
laninamivir
octano
reduc
fever
ferret
mortal
mice
viru
concentr
lung
ferret
mice
brain
mice
induc
influenza
varieti
virus
hpai
well
oseltamivirresist
hpai
clinic
isol
possess
mutat
review
yamashita
associ
studi
laninamivir
octano
administ
singl
intranas
dose
intranas
inocul
viru
either
efficaci
multipl
dose
oral
oseltamivir
intranas
zanamivir
result
studi
anim
exper
iment
influenza
replic
part
therapeut
trial
singl
laninamivir
octano
dose
clinic
see
later
singl
dose
laninamivir
octano
also
efficaci
prophi
lactic
mice
one
dose
prevent
mortal
reduc
viru
con
centrat
lung
brain
administ
much
day
viru
challeng
see
subsequ
discuss
mechan
action
oseltamivir
basi
prolong
persist
laninamivir
respi
ratori
tract
intranas
intratrach
administr
lanina
mivir
octano
anim
oral
inhal
human
complet
understood
human
volunt
bronchoalveolar
lavag
sampl
obtain
serial
hour
oral
inhal
singl
dose
laninamivir
octano
reveal
concentr
exceed
influenza
viru
neuraminidas
inhibitori
concentr
test
time
mice
intranas
administr
c
label
laninamivir
octano
demonstr
prolong
retent
laninami
vir
lung
tissu
microautoradiographi
indic
laninamivir
octano
taken
airway
epitheli
cell
seemingli
hydrolyz
antivir
molecul
laninamivir
intracellular
esteras
releas
slowli
extracellularli
perhap
result
hydrophob
function
decreas
viru
load
addit
clinic
studi
plan
laninamivir
octano
inavir
investig
drug
except
approv
japan
prodrug
laninamivir
inhibitor
influenza
b
neuraminidas
laninamivir
acid
fig
laninamivir
octano
consist
octano
acid
ester
side
chain
attach
c
posit
laninamivir
laninamivir
octano
like
polymer
zanamivir
conjug
share
pharmacokinet
characterist
persist
prolong
period
respiratori
tract
admin
istrat
intranas
intratrach
anim
oral
inhal
human
observ
presag
therapeut
effect
singl
dose
anim
experiment
induc
influenza
patient
well
laninamivir
octano
across
rang
person
healthi
high
risk
group
publish
data
laninamivir
octano
toler
plu
studi
oral
inhal
zanamivir
collect
suggest
oral
inhal
laninamivir
octano
like
prove
well
toler
safe
clinic
postmarket
studi
laninamivir
octano
japan
conclud
safeti
profil
laninamivir
octano
abnorm
behavior
delirium
syncop
similar
neuraminidas
inhibi
tor
japan
recommend
product
label
teenag
patient
inhal
laninamivir
octano
remain
constant
parent
supervis
least
day
monitor
behavior
chang
prevent
associ
selfinjuri
avoid
syncop
patient
inhal
laninamivir
octano
relax
sit
posit
anoth
postmarket
survey
laninamivir
octano
toler
patient
report
advers
event
commonli
report
advers
event
includ
psychiatr
disord
abnorm
behavior
gastrointestin
symptom
nervou
system
disord
dizzi
frequenc
respec
tive
usual
appear
day
laninamivir
octano
treatment
resolv
day
advers
reaction
frequenc
consid
compar
previous
observ
clinic
trial
thu
believ
confirm
notic
problem
safeti
limit
data
control
trial
avail
efficaci
oral
inhal
laninamivir
octano
influenza
treatment
although
three
random
control
trial
efficaci
toler
lanina
mivir
octano
one
observ
studi
compar
neuraminidas
inhibitor
report
trial
lanina
mivir
octano
administ
oral
inhal
powder
proprietari
devic
two
contain
dri
lanina
mivir
octano
powder
manufactur
instruct
recommend
two
inhal
changer
children
four
inhala
tion
necessari
wherea
eight
inhal
two
devic
requir
adult
occasion
young
children
inhal
medic
complet
owe
technic
difficulti
devic
pediatr
patient
influenza
less
hour
durat
random
treatment
singl
inhal
dose
laninamivir
octano
n
mg
accord
age
inhal
zanamivir
mg
twice
daili
day
n
median
time
fever
resolut
hour
laninamivir
octano
group
hour
zanamivirtr
group
rel
small
studi
suggest
singl
dose
inhal
laninamivir
octano
ate
efficaci
recommend
treatment
zana
mivir
anoth
studi
children
year
younger
influenza
less
hour
durat
random
singl
oral
inhal
n
mg
n
laninamivir
octano
oseltamivir
mgkg
n
ingest
twice
daili
day
children
infect
influenza
viru
possess
mutat
mediat
oseltami
vir
resist
oseltamivir
therapi
like
differ
placebo
median
time
allevi
influenza
ill
children
significantli
less
hour
laninamivir
group
respect
oseltamivirtr
group
hour
treatment
effect
viru
concentr
persist
upper
airway
secret
inconsist
although
day
none
subject
three
group
respect
still
excret
viru
clinic
therapeut
viro
logic
differ
among
children
infect
influenza
b
virus
number
case
small
doubleblind
random
noninferior
trial
young
healthi
adult
febril
influenza
hour
random
receiv
either
mg
mg
laninamivir
octano
oral
inhal
oseltamivir
mg
twice
daili
oral
day
primari
end
point
time
influenza
ill
allevi
unfortun
pediatr
studi
sugaya
ohashi
subject
infect
oseltamivirresist
influenza
viru
median
time
resolut
ill
patient
infect
viru
hour
respect
differ
viru
detect
cultur
significantli
poor
membran
permeabl
cellular
molecular
process
underli
observ
yet
determin
extens
studi
report
emerg
laninamivirresist
strain
laninamivir
exposur
vitro
laninamivir
octano
treatment
anim
patient
howev
one
studi
mice
infect
viru
virus
reduc
suscept
laninamivir
recov
pharmacokinet
epitheli
line
fluid
concentr
laninamivir
octano
laninamivir
calcul
analysi
bronchoalveolar
lavag
wash
ing
singl
oral
inhal
mg
laninamivir
octano
respect
hour
healthi
adult
volun
teer
disappear
halftim
bronchoalveolar
lavag
fluid
hour
respect
plasma
elim
valu
hour
respect
laninamivir
concentr
epitheli
line
fluid
exceed
median
inhibitori
concentr
influenza
neuraminidas
time
point
hour
dose
inhal
healthi
adult
volunt
evalu
phar
macokinet
laninamivir
octano
laninamivir
done
oral
inhal
singl
dose
mg
laninamivir
octano
ate
appear
rapidli
plasma
c
max
hour
compar
hour
laninamivir
plasma
elim
valu
hour
respect
plasma
area
concentr
time
curv
auc
laninamivir
octano
linearli
relat
dose
laninamivir
increas
disproproportion
mean
cumul
excret
urin
hour
respect
intraven
administr
claninamivir
rat
almost
radioact
recov
urin
human
volunt
clearanc
laninamivir
octano
laninamivir
linearli
relat
crcl
subject
none
mild
moder
sever
renal
impair
given
singl
oral
inhal
dose
mg
laninamivir
octano
renal
clearanc
laninamivir
octano
laninami
vir
directli
relat
crcl
wherea
elim
valu
geometr
mean
laninamivir
octano
clearanc
valu
declin
ml
min
normal
control
subject
mlmin
patient
sever
renal
impair
howev
elim
valu
hour
differ
among
four
group
laninamivir
renal
clearanc
declin
mlmin
across
four
group
wherea
elim
differ
among
group
rang
hour
like
explan
elimin
laninamivir
octano
laninamivir
reflect
slow
releas
compound
tissu
plasma
rather
renal
elimin
pharmacokinet
concept
call
flipflop
pharmacokinet
data
indic
reduct
laninamivir
octano
dose
may
appropri
patient
renal
impair
pharmacokinet
reason
lack
clear
doserel
toxic
see
later
minim
absorpt
oral
inhal
drug
suggest
dose
adjust
need
like
oral
inhal
zanamivir
oral
inhal
laninamivir
octano
powder
well
toler
doubleblind
studi
healthi
adult
vol
unteer
singl
dose
mg
multipl
dose
mg
twice
daili
day
well
toler
placebo
clinic
trial
patient
influenza
random
singl
laninamivir
octano
dose
mg
adult
children
year
old
older
mg
children
younger
year
old
inhal
zanamivir
control
neuraminidas
inhibitor
treat
ment
laninamivir
octano
inhal
well
toler
inhal
zanamivir
mg
twice
daili
day
doubleblind
trial
children
year
age
younger
influenza
singl
dose
inhal
laninamivir
octano
mg
well
toler
ate
oseltamivir
mgkg
bodi
weight
twice
daili
day
phase
iii
doubleblind
trial
adult
year
age
older
influenza
singl
dose
inhal
laninamivir
octano
mg
well
toler
oral
oseltamivir
mg
twice
daili
day
notwithstand
lack
data
larg
random
placebocontrol
doubleblind
trial
establish
toler
neuraminidas
cleav
termin
sialic
acid
residu
glycoconjug
destroy
receptor
recogn
viral
hemagglutinin
cell
newli
releas
virion
respiratori
tract
mucin
action
essenti
releas
viru
infect
cell
spread
within
respiratori
tract
inhibit
neuraminidas
action
caus
newli
form
virion
adher
cell
surfac
form
viral
aggreg
inhibitor
limit
spread
viru
within
respiratori
tract
may
prevent
viru
penetr
respiratori
secret
initi
replic
resist
variant
select
vitro
passag
oseltamivir
carbox
ylate
zanamivir
point
mutat
viral
hemagglutinin
neuraminidas
gene
hemagglutinin
variant
gener
mutat
near
receptor
bind
site
make
less
depend
neuraminidas
action
releas
cell
vitro
confer
crossresist
among
neuraminidas
inhibitor
variant
retain
full
suscept
vivo
neuraminidas
vari
ant
contain
singl
aminoacid
substitut
framework
cata
lytic
residu
activ
enzym
site
alter
drug
bind
caus
approxim
reduc
suscepti
biliti
enzym
inhibit
assay
influenza
variant
select
oseltamivir
carboxyl
subtyp
specif
commonli
without
crossresist
zana
mivir
alter
neuraminidas
reduc
activ
stabil
vitro
earli
studi
variant
usual
demonstr
decreas
infect
transmiss
anim
oseltamivir
therapi
associ
recoveri
virus
reduc
suscept
immunocompet
adult
pediatr
recipi
gener
emerg
resist
variant
associ
clinic
worsen
although
prolong
recoveri
resist
variant
sometim
combin
inhibitor
resist
observ
highli
immuno
compromis
host
transmiss
oseltamivirresist
viru
document
although
isol
oseltamivirresist
strain
treat
immunocompet
patient
uncommon
oseltamivir
resist
season
viru
appear
wide
immunocompet
individu
norway
absenc
antivir
pressur
mutant
viru
becam
transmiss
pathogen
preval
global
viru
strain
similarli
pan
demic
linkag
preval
use
oseltamivir
immunocompet
patient
appear
oseltamivirresist
strain
uncommon
preval
oseltamivirresist
rang
strain
test
ontario
canada
unit
state
isol
southeast
asia
preval
children
whose
immunocompet
specifi
hand
oseltamivirresist
isol
uncom
monli
recov
immunocompromis
patient
treat
drug
report
indic
oseltamivirresist
strain
retain
replic
fit
transmissi
biliti
pathogen
compar
wildtyp
oseltamivir
strain
murin
ferret
model
influenza
infect
clinic
ill
caus
oseltamivirresist
strain
immunocom
petent
children
respond
less
well
oseltamivir
evidenc
higher
fever
day
treatment
although
found
evi
denc
prolong
ill
children
infect
drugresist
viru
other
report
significantli
longer
time
achiev
nond
tectabl
viru
load
patient
oseltamivirresist
com
pare
oseltamivirsensit
strain
pharmacokinet
oral
oseltamivir
rapidli
absorb
metabol
esteras
gastrointestin
tract
liver
blood
activ
carboxyl
estim
bioavail
carboxyl
approxim
time
maxim
plasma
concentr
averag
hour
dose
proportion
oseltamivir
report
dose
rang
mg
low
blood
level
pro
drug
detect
rare
possess
constitut
variant
car
boxylesteras
enzym
normal
catalyz
convers
less
often
day
laninamivir
octano
group
oseltamivir
group
might
con
sider
analog
placebotr
cohort
among
individu
infect
influenza
viru
median
time
ill
allevia
tion
differ
treat
laninamivir
octano
ate
mg
hour
oseltamivir
hour
significantli
longer
group
treat
laninamivir
octano
mg
hour
differ
among
group
viru
concentr
upper
airway
secret
persist
con
fidenc
interv
pool
analysi
data
less
prescrib
noninferior
margin
conclud
singl
inha
lation
laninamivir
octano
effect
treatment
season
influenza
includ
caus
oseltamivirresist
viru
adult
observ
studi
children
febril
influenza
less
hour
due
influenza
infect
infect
treat
accord
recommenda
tion
clinician
prefer
patient
guardian
children
treat
oseltamivir
weight
appropri
dose
zanamivir
case
one
dose
intraven
pera
mivir
children
singl
dose
oral
inhal
laninamivir
octano
mg
children
year
older
mg
younger
year
children
primari
end
point
dura
tion
fever
first
dose
neuraminidas
inhibitor
differ
durat
fever
among
oseltamivir
zanami
vir
laninamivir
octano
group
median
time
resolut
fever
peramivir
group
hour
significantli
less
three
group
avail
data
suggest
singl
inhal
dose
laninamivir
octano
efficaci
children
influenza
less
hour
efficaci
popul
especi
highrisk
condi
tion
remain
evalu
impact
complic
influenza
oseltamivir
phosphat
tamiflu
ethyl
ester
prodrug
oselta
mivir
carboxyl
sialic
acid
analogu
see
fig
potent
specif
inhibitor
neuraminidas
influenza
b
virus
metabolit
oseltamivir
carboxyl
approxim
potent
phosphat
prodrug
oseltamivir
car
boxyl
competit
revers
interact
activ
enzym
site
inhibit
neuraminidas
activ
low
nanomolar
concentra
tion
inhibitori
concentr
neuraminidas
inhibitor
cell
cultur
broad
rang
depend
assay
method
may
correl
vivo
activ
oseltamivir
carboxyl
activ
virus
contain
nine
influenza
neuraminidas
subtyp
recogn
natur
includ
recent
pathogen
avian
virus
reassort
viru
con
tain
neuraminidas
pandem
strain
inhibitorresist
strain
recent
circul
pandem
virus
soiv
resist
oseltamivir
recent
report
isol
influenza
b
virus
less
suscept
oselta
mivir
carboxyl
influenza
virus
influenza
b
viru
ill
respond
less
well
clinic
virolog
oseltamivir
influenza
ill
carboxyl
cytotox
inhibit
neuraminidas
mammalian
sourc
pathogen
fold
higher
concentr
oral
oseltamivir
activ
murin
ferret
model
influenza
prophylact
regimen
given
oral
twice
daili
day
complet
protect
ferret
morbid
mortal
caus
infect
interfer
develop
protect
immun
subsequ
infec
tion
neuraminidas
inhibitor
combin
inhibitor
ribavirin
show
enhanc
antivir
activ
vitro
anim
model
influenza
viru
infect
includ
viru
amantadin
combin
oseltamivir
prevent
emerg
amantadin
resist
cell
cultur
neuraminidas
inhibitor
drug
oseltamivir
zanamivir
peramivir
laninamivir
share
common
mechan
action
influenza
oseltamivir
gener
well
toler
patient
age
includ
ing
pregnant
women
fetus
seriou
endorgan
toxic
iti
recogn
oral
administr
associ
nausea
epigastr
distress
emesi
adult
receiv
mg
twice
daili
gastrointestin
complaint
usual
mild
moder
intens
resolv
despit
continu
dose
amelior
administr
food
nausea
vomit
possibl
dizzi
dose
relat
adult
discontinu
rate
observ
control
treatment
studi
mechan
nausea
vomit
uncertain
risk
seem
lower
older
adult
longterm
prophylaxi
associ
ate
increas
risk
advers
event
although
headach
may
occur
older
recipi
selfinjuri
delirium
psychiatr
ill
report
patient
primarili
pediatr
adol
cent
influenza
treat
oseltamivir
mostli
japan
anali
se
neuropsychiatr
reaction
among
patient
influenza
treat
oseltamivir
three
larg
us
administr
databas
demonstr
associ
declin
case
japan
regulatori
recommend
restrict
oseltamivir
use
chil
dren
year
age
associ
declin
oseltamivirrel
case
correspond
rise
case
associ
zanamivir
inhal
minim
system
bioavail
neur
aminidas
inhibitor
latter
fact
rais
doubt
causal
associ
oseltamivir
therapi
neuropsychiatr
behavior
advers
reaction
patient
influenza
erythema
tou
rash
rare
instanc
sever
erupt
stevensjohnson
syndrom
hepat
inflamm
hemorrhag
coliti
anaphylaxi
thrombocytopenia
report
relationship
oseltamivir
uncertain
oseltamivir
efficaci
prevent
treatment
influenza
b
viru
infect
unit
state
approv
prevent
influenza
patient
year
older
treatment
acut
uncompl
influenza
patient
week
age
older
symptomat
day
earli
clinic
experi
volunt
induc
influenza
demonstr
oral
oseltamivir
highli
protect
experiment
human
influenza
earli
treatment
associ
reduct
viral
titer
symptom
nasal
cytokin
middl
ear
pressur
abnorm
subsequ
control
trial
patientsmostli
healthi
adult
children
natur
acquir
season
influenza
infectiondemonstr
earli
oseltamivir
treatment
acut
influenza
reduc
time
ill
allevi
day
fever
durat
viral
titer
upper
respiratori
tract
earlier
treatment
maxim
speed
resolut
ill
treat
ment
children
reduc
risk
otiti
media
decreas
overal
antibiot
use
healthi
highrisk
adult
earli
treatment
report
decreas
risk
lower
respiratori
tract
complica
tion
lead
antibiot
administr
hospit
question
metaanalysi
observ
studi
highrisk
patient
season
influenza
conclud
oseltamivir
treatment
may
reduc
hospit
wherea
treatment
hospit
ize
patient
reduc
respiratori
failur
intens
care
unit
admiss
mortal
recent
metaanalysi
base
larg
number
observ
data
individu
case
suggest
oseltamivir
treatment
may
associ
reduct
mortal
risk
howev
cochran
analysi
conclud
evid
indi
cate
oseltamivir
treatment
reduc
complic
hospitaliza
tion
hospit
patient
infect
influenza
oseltamivir
provid
similar
benefit
even
treatment
start
hour
clinic
ill
begun
uncertain
extent
oseltamivir
treatment
may
reduc
transmiss
although
review
four
trial
prophylaxi
suggest
oseltamivir
may
reduc
transmiss
oseltamivir
less
efficaci
treatment
influenza
b
influenza
viru
infect
children
adult
anali
si
cumul
case
influenza
infect
global
registri
demonstr
crude
mortal
significantli
less
treat
oseltamivir
treat
start
day
symptom
onset
oseltamivir
phosphat
carboxyl
markedli
impair
hydro
lysi
parent
compound
result
potenti
compro
mise
antivir
effect
oseltamivir
administr
ingest
food
delay
absorpt
slightli
decreas
overal
bioavail
oseltamivir
administ
via
nasogastr
tube
patient
respiratori
failur
requir
mechan
ventil
well
absorb
convert
oseltamivir
carboxyl
healthi
adult
peak
trough
plasma
concentr
averag
dose
infant
year
age
system
exposur
auc
hr
carboxyl
exhibit
decreas
variabl
clearanc
increas
recommend
dose
oselta
mivir
mgkg
twice
daili
infant
birth
month
age
mgkg
twice
daili
month
age
children
older
year
carboxyl
exposur
increas
gradual
increas
age
weightbas
dose
recommend
healthi
elderli
adult
overal
drug
exposur
greater
younger
adult
like
owe
differ
renal
elimi
nation
morbid
obes
bodi
mass
index
kgm
alter
oseltamivir
pharmacokinet
effect
pregnanc
phar
macokinet
oseltamivir
unclear
one
studi
report
differ
enc
among
women
third
trimest
pregnanc
histor
control
wherea
anoth
report
reduct
system
auc
hr
oseltamivircarboxyl
exposur
pregnant
women
compar
concurr
nonpregn
control
perhap
suggest
need
mg
three
time
day
oseltamivir
treatment
plasma
protein
bind
prodrug
carboxyl
low
v
moder
l
anim
lower
respiratori
tract
level
similar
exceed
level
blood
human
carboxyl
detect
middl
ear
maxil
lari
sinu
fluid
concentr
similar
plasma
oseltamivir
concentr
occur
breast
milk
ex
vivo
human
placenta
model
oseltamivir
extens
metabol
carboxyl
moieti
transplacent
passag
oseltamivir
carboxyl
ate
occur
low
rate
infer
fetal
exposur
matern
treatment
oseltamivir
may
minim
carboxyl
detect
cerebrospin
fluid
one
child
wherea
c
max
valu
cerebrospin
fluid
correspond
plasma
con
centrat
oseltamivir
oseltamivir
carboxyl
eight
healthi
adult
ingest
mg
oseltamivir
oral
oseltamivir
plasma
elim
carboxyl
averag
hour
healthi
adult
prodrug
carboxyl
excret
primarili
unchang
kidney
carboxyl
elimin
glomerular
filtra
tion
tubular
secret
via
probenecidsensit
anion
tran
porter
clearanc
vari
linearli
crcl
elim
increas
hour
patient
crcl
less
mlmin
dosag
reduct
need
oseltamivir
carboxyl
remov
dif
ferent
degre
effici
differ
renal
replac
therapi
periton
hemodialysi
continu
renal
replac
thera
pie
dose
oseltamivir
patient
renal
impair
receiv
renal
replac
therapi
publish
uncompl
influenza
ill
seem
alter
pharma
cokinet
oseltamivir
cystic
fibrosi
patient
appear
clear
osel
tamivir
carboxyl
rapidli
patient
diseas
interact
probenecid
reduc
renal
clearanc
oseltamivir
clinic
import
drug
interact
recogn
sotalol
appear
induc
torsad
de
point
cardiac
arrhythmia
oseltamivir
therapi
influenza
specif
studi
found
interact
antacid
acetaminophen
aspirin
known
inhibitor
select
renal
tubular
secret
pathway
amoxicillin
cimetidin
cyclosporin
mycophenol
tacrolimu
warfarin
rimantadin
preclin
studi
found
evid
mutagen
teratogen
oncogen
effect
highdos
oseltamivir
caus
renal
tubular
min
eral
mice
matern
toxic
rabbit
classifi
pregnanc
categori
c
possess
mutat
intraven
peramivir
like
suboptim
intraven
zanamivir
prefer
absolut
oral
bioavail
peramivir
result
clini
cal
develop
focus
efficaci
safeti
intramu
cular
intraven
inject
fortun
long
elimin
halflif
support
singledos
intraven
treatment
regimen
dose
mgkg
adult
plasma
auc
increas
pro
portion
dose
higher
dose
greater
mgkg
use
clinic
trial
adult
plasma
healthi
adult
approxi
mate
hour
support
singledos
treatment
appar
v
approxim
lkg
system
clearanc
mlhrkg
cor
respond
valu
children
mean
age
year
hour
lkg
mlhrkg
physiolog
counterpart
larg
v
unknown
locu
drug
sequestr
identifi
plasma
protein
bind
less
peramivir
concen
tration
plasma
higher
concurr
level
nasal
wash
pharyng
gargl
solut
peramivir
detect
site
hour
dose
concentr
greater
level
inhibit
neuraminidas
strain
influenza
viru
clinic
relev
data
unknown
dose
inject
intraven
young
healthi
adult
influenza
ill
less
hour
durat
efficaci
well
toler
infus
dose
median
minut
produc
median
plasma
concentr
ngml
end
infus
ngml
hour
later
dose
yield
correspond
valu
ngml
median
inhibitori
concentr
isol
ic
neuramini
dase
patient
virus
rang
nmoll
influenza
nmoll
influenza
nmoll
influ
enza
b
isol
pediatr
patient
month
year
age
infect
influenza
intraven
infus
mgkg
daili
produc
compar
plasma
concentr
seen
young
healthi
adult
see
earlier
median
peramivir
plasma
concentr
ngml
end
infus
ngml
hour
later
relationship
plasma
concentr
data
efficaci
unclear
mice
plasma
auc
pera
mivir
pharmacokinet
characterist
relat
efficaci
data
peramivir
distribut
breast
milk
human
unavail
less
clabel
peramivir
administ
rat
recov
breast
milk
peramivir
elimin
unchang
urin
glomerular
filtrat
probenecid
affect
excr
tion
patient
renal
insuffici
mean
rang
hour
subject
mean
crcl
mlmin
individu
al
dialysisdepend
renal
failur
averag
hour
octob
us
food
drug
administr
issu
emerg
use
author
eua
administr
intra
venou
peramivir
treatment
hospit
patient
su
pect
confirm
case
influenza
infect
intraven
neuraminidas
inhibitor
drug
avail
abl
adult
normal
renal
function
recommend
intrav
nou
dose
mgday
children
year
age
mgkg
intraven
daili
dose
age
group
patient
renal
impair
includ
endstag
renal
diseas
requir
differ
renalreplac
therapi
suggest
eua
termin
peramivir
avail
clinic
trial
see
clinic
studi
later
advers
drugdrug
interact
report
subject
given
peramivir
number
individu
expos
still
modest
pharmacokinet
interact
intraven
peramivir
oral
oseltamivir
rimantadin
observ
healthi
volunt
drugdrug
interact
individu
receiv
peramivir
unlik
neither
induc
inhibit
import
drugmetabol
cytochrom
enzym
peramivir
gener
nontox
well
toler
preclin
studi
reveal
genotox
reproduct
toxic
development
oseltamivir
treatment
hematopoiet
stem
cell
transplant
recipi
ent
influenza
may
prevent
develop
pneumonia
viru
shed
therebi
prevent
influenzarel
death
index
patient
nosocomi
transmiss
other
patient
leukemia
develop
influenza
treat
oselta
mivir
none
die
compar
treat
prophylact
administr
oncedaili
oral
oseltamivir
mg
highli
effect
reduc
risk
develop
febril
ill
influenza
season
unimmun
adult
efficaci
immun
nurs
home
resid
efficaci
transplant
recipi
efficaci
prevent
influenza
may
reduc
sec
ondari
complic
institution
older
adult
oncedaili
oseltamivir
day
also
effect
postexposur
prophi
laxi
household
contact
includ
children
ill
index
case
receiv
concurr
treatment
fig
investig
agent
unit
state
approv
japan
china
south
korea
potent
select
inhibitor
influenza
b
viru
neuraminidas
includ
ing
nine
avian
na
subtyp
influenza
sialic
acid
analogu
design
structur
distinct
oseltamivir
zanamivir
crossresist
among
oseltamivirresist
zanamivirresist
strain
consist
observ
like
oseltamivir
zanamivir
peramivir
inhibit
influenza
neuraminidas
enzym
assay
nanomolar
concentra
tion
requir
micromolar
concentr
inhibit
influenza
replic
cell
cultur
potent
inhibitor
influenza
b
virus
vitro
oseltamivir
zanamivir
clini
cal
relev
differ
yet
evalu
combina
tion
treatment
influenza
viru
infect
cell
cultur
mice
peramivir
ribavirin
yield
addit
synergist
interact
increas
toxic
antivir
effect
combin
peramivir
plu
rimantadin
vitro
variabl
rang
addit
synergist
mice
experiment
influenza
infect
combin
peramivir
rimantadin
synergist
murin
ferret
model
influenza
infect
peramivir
effect
administ
intranas
oral
intramuscularli
see
previou
discuss
mechan
action
oseltamivir
peramivirresist
influenza
viru
select
vitro
peramivirtr
mice
experiment
influenza
infect
healthi
volunt
given
peramivir
prevent
treat
ment
experiment
induc
influenza
b
infect
healthi
treat
patient
peramivirresist
viru
possess
mutat
emerg
intraven
therapi
pandem
influenza
immunocompromis
patient
peramivir
resist
mutant
gener
vitro
may
possess
unalt
dimin
ish
virul
replic
capac
mice
ferret
peramivir
resist
associ
sole
alter
hemagglutinin
gene
confer
crossresist
oseltamivir
zanamivir
could
caus
lethal
diseas
mice
infect
resist
viru
mice
still
amen
peramivir
therapi
howev
natur
occur
oseltamivirresist
influenza
virus
possess
ing
mutat
reduc
suscep
tibil
peramivir
less
oseltamivir
studi
suggest
infect
due
virus
possess
mutat
may
success
treat
higher
dose
regimen
inject
peramivir
mice
highrisk
patient
howev
intraven
peramivir
effect
oseltamivir
case
report
observ
studi
influenza
caus
mutant
strain
world
health
organ
recommend
treatment
infect
due
influenza
strain
point
among
peramivirtr
regimen
compar
report
patient
treat
oseltamivir
random
control
studi
intraven
administ
peramivir
plu
standard
care
versu
standard
care
alon
patient
hospit
influenza
recent
termin
futil
show
differ
peramivir
control
group
note
earlier
intraven
peramivir
probabl
effect
treatment
patient
oseltamivir
resist
due
possess
mutat
intraven
zanamivir
recommend
ribavirin
vira
zole
rebetol
copegu
guanosin
analogu
fig
base
dribos
sugar
necessari
antivir
activ
ribavirin
inhibit
vitro
replic
wide
rang
rna
dna
virus
includ
myxovirus
paramyxovirus
arenavi
ruse
flavivirus
bunyavirus
coronavirus
togavirus
reovi
ruse
herpesvirus
adenovirus
poxvirus
retrovirus
plaqu
assay
inhibitori
concentr
rang
influenza
parainfluenza
respiratori
syncyti
viru
rsv
high
concentr
inhibit
group
c
adenovirus
pathogen
flavivi
ruse
includ
west
nile
viru
neural
cell
ribavirin
inhibit
sever
acut
respiratori
viru
sar
coronaviru
vitro
low
concentr
ribavirin
revers
inhibit
macromolecular
synthesi
prolifer
rapidli
divid
cell
ribavirin
decreas
nucleic
acid
protein
synthesi
inhibit
releas
increas
apoptosi
human
peripher
blood
mononuclear
cell
vitro
advers
affect
polymorphonuclear
leukocyt
function
ribavirin
postu
late
enhanc
cellmedi
immun
respons
increas
type
suppress
type
cytokin
respons
cell
decreas
proinflammatori
cytokin
elabor
inflammatori
cell
number
aerosol
administr
effect
parenter
dose
anim
model
influenza
rsv
infect
parenter
ribavirin
antivir
therapeut
activ
anim
model
infect
lassa
viru
arenavirus
bunyaviru
see
chapter
combin
ribavirin
immunoglobulin
rsv
infect
neuraminidas
inhibitor
influenza
infect
neuraminidas
inhibitor
influenza
b
infect
show
enhanc
antivir
activ
use
ribavirin
treatment
hepat
b
c
discuss
chapter
antivir
mechan
action
ribavirin
complex
like
vari
differ
virus
ribavirin
caus
alter
cellular
nucleotid
pool
inhibit
viral
rna
synthesi
may
caus
lethal
mutagenesi
certain
rna
viru
genom
intracellular
pho
phoryl
monophosph
diphosph
triphosph
deriv
mediat
host
cell
enzym
uninfect
rsv
infect
cell
predomin
deriv
triphosph
rapidli
lost
intracellular
elim
less
hour
ribavirin
monophosph
competit
inhibit
inosin
mono
phosphat
dehydrogenas
interfer
synthesi
toxic
multipl
speci
anim
appar
advers
effect
revers
nephrotox
speci
rabbit
gender
femal
specif
nephrotox
dose
greater
mg
kgday
intraven
day
largest
dose
administ
human
mg
oral
mg
intraven
associ
consist
advers
symptom
laboratori
abnorm
compar
placebo
placebocontrol
clinic
trial
peramivir
oral
mgday
day
mgday
intramuscularli
mg
intraven
advers
symptom
report
frequent
peramivir
recipi
placebo
recipi
control
blind
trial
well
uncontrol
studi
intra
venou
peramivir
gener
well
toler
safe
random
doubleblind
studi
compar
singl
dose
peramivir
mg
match
placebo
given
intraven
young
healthi
adult
outpati
set
nausea
may
report
frequent
drug
recipi
respect
three
group
extens
blood
urin
laboratori
test
reveal
differ
among
group
random
doubl
blind
doubledummi
trial
young
healthi
adult
influenza
treat
peramivir
mg
mg
intraven
oseltamivir
mg
oral
twice
daili
day
overal
incid
advers
effect
lowest
group
compar
group
respect
diarrhea
nausea
decreas
neutrophil
count
tend
lowest
peramivir
group
random
unblind
studi
ho
pital
patient
treat
influenza
intraven
peramivir
mg
daili
oseltamivir
mg
oral
twice
daili
day
incid
advers
event
low
gener
similar
among
treatment
group
assess
side
effect
intraven
peramivir
uncontrol
studi
hospit
adult
highrisk
comorbid
condit
also
suggest
drug
gener
well
toler
singl
case
dilat
cardiomyopathi
myocard
volunt
infect
influenza
b
challeng
viru
treat
peramivir
report
relationship
cardiac
disord
drug
unknown
studi
serosuscept
volunt
peramivir
prophylaxi
mg
oral
daili
placebo
initi
hour
influenza
b
viru
challeng
continu
day
tend
prevent
ill
dose
mg
greater
reduc
viral
shed
titer
nasal
wash
subject
inocul
influenza
viru
effect
prevent
ill
caus
influenza
b
viru
observ
although
durat
viru
shed
tend
less
individu
receiv
mg
mg
peramivir
earli
studi
patient
influenza
oral
peramivir
therapi
dose
mg
daili
day
singl
intramuscular
dose
mg
reduc
median
time
relief
symptom
differ
statist
signific
control
sub
sequent
control
trial
intraven
formul
demon
strate
peramivir
therapeut
efficaci
toler
patient
influenza
due
suscept
viru
strain
peramivir
treatment
natu
ralli
acquir
influenza
young
adult
ill
hour
dura
tion
less
mg
inject
intraven
versu
placebo
reduc
median
time
relief
symptom
significantli
hour
placebo
group
hour
hour
pera
mivir
group
outpati
set
perami
vir
treatment
also
significantli
reduc
proport
subject
still
excret
viru
nasal
throat
secret
day
placebo
recipi
treat
peramivir
mg
respect
hospit
patient
random
day
treatment
intraven
peramivir
gday
compar
histor
report
oral
oseltamivir
mg
twice
daili
reduct
viru
concentr
nasopharyng
secret
similar
across
three
treatment
addit
studi
util
higher
dose
pera
mivir
mg
twice
daili
mg
four
time
day
hospit
ize
patient
also
show
differ
virolog
clinic
end
occur
shortterm
oral
administr
longterm
use
oral
ribavirin
dosag
greater
mg
daili
caus
hemoglobin
decreas
gdl
recipi
usual
within
week
use
combin
interferon
hemoglobin
level
less
gdl
develop
patient
renal
impair
increas
risk
hemolysi
sever
anemia
requir
dosag
reduc
tion
cessat
although
erythropoietin
use
effect
report
side
effect
includ
pruritu
myalgia
rash
nausea
depress
nervous
cough
respiratori
symptom
high
dose
intraven
ribavirin
associ
headach
hypomagnes
mia
hypocalcemia
bolu
intraven
dose
may
caus
rigor
infus
minut
advis
aerosol
ribavirin
may
caus
conjunctiv
irrit
rash
bron
chospasm
revers
deterior
pulmonari
function
rare
acut
water
intox
advers
hematolog
effect
associ
aerosol
ribavirin
drug
may
precipit
contact
lens
worn
aerosol
exposur
ribavirin
exposur
may
occur
health
care
worker
work
environ
aerosoltr
infant
health
care
worker
expo
sure
higher
deliveri
oxygen
hood
ventil
vacuumexhaust
hood
system
use
aerosol
contain
scaveng
system
turn
aerosol
gener
provid
routin
care
use
person
protect
equip
recommend
ribavirin
use
conjunct
mechan
ventil
inlin
filter
modifi
circuitri
frequent
monitor
requir
prevent
plug
ventil
valv
tube
precipit
ribavirin
possibl
effect
modif
drug
deliveri
lower
respiratori
tract
undefin
preclin
studi
ribavirin
mutagen
gonadotox
tera
togen
low
oral
dosag
teratogen
embryotox
multipl
speci
use
ribavirin
rel
contraind
pregnanc
pregnant
women
directli
care
patient
receiv
ribavirin
aerosol
ribavirin
categor
pregnanc
cat
egori
x
effect
mean
contracept
men
women
recommend
least
month
discontinu
treatment
exposur
antacid
slightli
decreas
oral
bioavail
ribavirin
coadministr
clinic
ribavirin
amantadin
oseltamivir
interact
pharmacokinet
ribavirin
antagon
anti
effect
zidovudin
enhanc
activ
purin
dide
oxynucleosid
ribavirin
use
patient
coinfect
hiv
hcv
antiretrovir
drug
particularli
combin
didanosin
seem
increas
risk
mitochondri
toxic
lactic
acidosi
ribavirin
may
inhibit
effect
warfarin
ribavirin
aerosol
approv
unit
state
treatment
rsv
bronchiol
pneumonia
hospit
children
oral
ribavirin
combin
variou
interferon
approv
treatment
chronic
hepat
c
follow
describ
clinic
studi
prevent
treatment
respiratori
viru
infect
ribavirin
treatment
infect
hcv
discuss
elsewher
see
chapter
aerosol
ribavirin
exposur
daili
day
variabl
shorten
durat
viru
shed
may
improv
certain
clini
cal
measur
infant
hospit
rsv
ill
consist
reduct
need
ventilatori
support
durat
hospitaliza
tion
document
howev
infant
receiv
mechan
ventil
rsvrelat
respiratori
failur
signific
reduc
tion
durat
ventilatori
support
hospit
mortal
found
intermitt
highdos
therapi
expo
sure
three
time
daili
day
well
toler
may
effect
prolong
exposur
use
aerosol
ribavirin
limit
concern
regard
efficaci
eas
administr
risk
occup
exposur
cost
american
academi
pediatr
state
aerosol
treatment
guanosin
triphosph
gtp
nucleic
acid
synthesi
decreas
concentr
compet
gtp
like
potenti
ribavi
rin
antivir
effect
ribavirin
triphosph
inhibit
influenza
viru
rna
polymeras
activ
gtpdepend
viral
mrna
monophosph
incorpor
ineffici
viral
rna
genom
may
lead
lethal
mutagenesi
con
tribut
antivir
activ
hcv
rna
polymeras
incorpor
riba
virin
monophosph
viral
rna
caus
mutat
inhibit
viral
rna
synthesi
ribavirin
diphosph
tripho
phate
also
inhibit
human
immunodefici
viru
hiv
revers
tran
scriptas
activ
ribavirin
immunosuppress
effect
experiment
anim
show
therapeut
activ
transplant
virusinduc
tumor
certain
autoimmun
diseas
ribavirin
increas
type
cytokinemedi
immun
respons
vivo
effect
may
con
tribut
therapeut
activ
seem
augment
cytokin
respons
ex
vivo
peripher
blood
mononuclear
cell
patient
chronic
hepat
c
resist
antivir
resist
ribavirin
document
sindbi
viru
hcv
date
one
hcv
rna
polymeras
variant
select
genotyp
ribavirintr
patient
associ
ribavirin
resist
vitro
ribavirinresist
rsv
detect
aerosol
therapi
children
oral
ribavirin
well
absorb
bioavail
averag
adult
firstpass
metabol
administr
food
increas
absorpt
peak
plasma
concentr
singl
oral
dose
mg
mg
mg
peak
plasma
concentr
occur
hour
averag
ml
plasma
concentr
averag
approxim
intraven
dose
mg
mg
patient
lassa
fever
longterm
administr
overal
exposur
elim
increas
substanti
steadyst
plasma
level
occur
week
weight
adjust
dose
chronic
hepat
c
higher
concentr
week
correl
declin
hemoglobin
likelihood
sustain
viral
respons
plasma
protein
bind
neglig
ribavirin
larg
v
l
steadi
state
cerebrospin
fluid
level
plasma
disposit
ribavirin
complex
involv
renal
elimin
metabol
rapid
initi
distribut
prolong
termin
elim
hour
ribavirin
triphosph
concen
trate
erythrocyt
erythrocytetoplasma
ratio
greater
erythrocyt
level
gradual
decreas
appar
day
renal
excret
account
ribavirin
overal
clearanc
hepat
metabol
contributori
recov
unchang
urin
much
greater
fraction
excret
triazol
carboxamid
carboxyl
acid
metabolit
plasma
clearanc
reduc
threefold
patient
advanc
renal
impair
crcl
mlmin
dosag
adjust
need
renal
insuffici
ribavirin
use
caution
patient
crcl
less
mlmin
hemodialysi
hemofiltra
tion
remov
small
amount
drug
higher
initi
blood
level
occur
sever
hepat
dysfunct
aerosol
administr
system
absorpt
low
deposit
dose
peak
plasma
level
rang
hour
exposur
hour
pediatr
patient
respiratori
secret
level
often
exceed
persist
hour
special
aerosol
gener
spag
icn
pharmaceut
need
produc
particl
proper
aero
dynam
size
reach
lower
respiratori
tract
deliv
dose
twice
high
infant
mgkghr
adult
system
ribavirin
caus
doserel
anemia
extravascular
hemolysi
higher
dosag
suppress
bone
marrow
releas
erythroid
element
revers
increas
serum
bilirubin
one
fourth
recipi
serum
iron
uric
acid
concentr
nucleocapsid
n
protein
highli
conserv
drug
well
absorb
oral
singl
dose
per
day
suffici
achiev
anti
viral
ec
level
vitro
resist
elicit
appar
low
rate
resist
viru
appear
similarli
fit
wildtyp
rsv
term
replic
phase
ii
studi
underway
transplant
patient
rsv
infect
zanamivir
acid
relen
za
sialic
acid
analogu
see
fig
potent
specif
inhibitor
neuraminidas
influenza
b
virus
inhibit
influenza
neuraminidas
activ
nanomolar
concentr
higher
broader
rang
inhibitori
concentr
cell
cultur
compar
oseltamivir
carboxyl
zanamivir
activ
influenza
b
data
compar
trial
children
indic
differ
clinic
import
zana
mivir
less
activ
neuraminidas
influenza
clinic
isol
clinic
import
differ
uncertain
zanamivir
inhibit
certain
influenza
neuraminidas
variant
resist
oseltamivir
carboxyl
combin
zanamivir
plu
rimantadin
inhibit
strain
influenza
virus
synergist
concentr
seem
antagonist
assess
reduct
cellassoci
viru
yield
zanamivir
cytotox
highli
select
influenza
neuraminidas
inhibit
ing
neuraminidas
human
mammalian
sourc
pathogen
fold
higher
concentr
millimolar
concentr
inhibit
parainfluenza
viru
type
cell
cultur
like
block
attach
topic
zanamivir
respiratori
tract
activ
murin
ferret
model
influenza
resist
neuraminidas
inhibitor
drug
develop
less
fre
quentli
adamantan
compound
less
frequent
zanamivir
oseltamivir
recent
systemat
review
preval
neuraminidas
inhibitor
resist
among
influenza
virus
cultur
immuno
compet
ambulatori
adult
enrol
prophylact
therapeut
trial
zanamivir
found
report
zanamivir
resist
survey
collect
influenza
isol
similar
absenc
dearth
zanamivir
resist
report
influenza
virus
circul
influenza
season
unit
state
prior
emerg
pandem
resist
oseltamivir
suscept
zanamivir
among
nonpandem
isol
australia
southeast
asia
patient
resist
zanamivir
suscept
oseltamivir
zanamivir
resist
demonstr
among
influenza
global
isol
among
oseltamivirresist
isol
report
world
health
organ
august
avian
influenza
isol
suscept
zanamivir
influenza
b
virus
isol
china
one
aminoacid
substitut
resist
zanamivir
sever
neuraminidas
mutat
mediat
diminish
susceptibil
iti
zanamivir
season
viru
reduct
zanamivir
suscept
nonpandem
viru
reduct
isol
relationship
viru
resist
mutat
prior
zanamivir
therapi
immun
compet
consist
appar
influenza
b
viru
mutat
resist
zanamivir
oseltamivir
recov
immuno
compromis
child
prolong
viru
excret
despit
receipt
nebul
zanamivir
effect
neuraminidas
mutat
infect
transmiss
compar
wildtyp
parent
strain
variabl
mutant
character
regard
observ
studi
pediatr
patient
influenza
treat
oseltamivir
zanamivir
suggest
lower
preval
zanamivir
oseltamivir
resist
relat
intrins
properti
drug
differ
preval
use
drug
rsv
infect
recommend
routin
use
may
consid
use
select
patient
document
potenti
lifethreaten
rsv
infect
decreas
rsvspecif
serum
neu
traliz
antibodi
titer
diminish
nasopharyng
secret
rsvspecif
ige
iga
respons
may
occur
ribavirintr
children
longterm
advers
benefici
effect
ribavirin
therapi
document
children
combin
aerosol
ribavirin
intraven
immuno
globulin
palivizumab
may
benefici
treat
rsv
pneumonia
hematopoiet
stem
cell
transplant
recipi
wherea
intrav
nou
ribavirin
alon
ineffect
therapi
either
aerosol
oral
ribavirin
appear
prevent
progress
upper
lower
respiratori
tract
ill
patient
similar
benefit
preemptiv
treatment
rsv
upper
respiratori
tract
infect
lung
transplant
recipi
oral
inhal
ribavirin
report
intraven
aerosol
form
ribavirin
use
treat
sever
influenza
viru
infect
aerosol
ribavirin
inconsi
tentli
reduc
viral
titer
ill
measur
adult
uncom
plicat
influenza
b
modest
efficaci
children
hospit
influenza
howev
oral
ribavirin
mg
three
time
per
day
combin
amantadin
oseltamivir
may
possibl
effect
treatment
influenza
diseas
oseltamivir
alon
oral
intraven
aerosol
ribavirin
use
immunosuppress
patient
sever
parainfluenza
viru
adenoviru
infect
inconsist
clinic
benefit
intraven
ribavirin
use
treat
adenovirusassoci
hemorrhag
cystiti
pneumonia
invas
infect
immunocompromis
patient
may
effect
even
sever
diseas
treatment
intraven
oral
ribavirin
human
metapneumoviru
pneumonia
immunocompro
mise
patient
associ
resolut
aerosol
riba
virin
use
treat
parainfluenza
viru
infect
solidorgan
transplant
recipi
seem
ineffect
parainflu
enza
viru
pneumonia
hematopoiet
stem
cell
transplant
recipi
ent
oral
ribavirin
effect
acceler
function
graft
recoveri
reduc
late
bronchiol
obliteran
lung
tran
plant
recipi
bone
marrow
transplant
recipi
paramyxoviru
respiratori
infect
intraven
ribavirin
therapi
associ
success
treatment
paramyxoviru
type
respiratori
infect
cardiac
transplant
recipi
ribavirin
use
extens
treat
sar
coronaviru
infect
without
proven
antivir
effect
vitro
patient
associ
frequent
advers
effect
intraven
ribavirin
seem
ineffect
treatment
hantaviru
cardiopulmonari
syn
drome
howev
inhibit
and
viru
vitro
import
caus
syndrom
effect
hamster
model
hantaviru
cardiopulmonari
syndrom
caus
viru
see
chapter
oral
benzodiazepin
compound
c
h
fn
develop
treatment
rsv
infect
fig
inhib
rsv
b
subtyp
submicromolar
concentr
antivir
activ
express
interact
rsv
improv
peak
expiratori
flow
rate
inhal
placebo
howev
postmarket
report
indic
potenti
risk
acut
bronchospasm
respiratori
arrest
worsen
chronic
obstruct
pulmonari
diseas
accompani
pulmonari
edema
zanamivir
inhal
particularli
patient
underli
airway
diseas
appar
declin
respiratori
function
also
rare
report
patient
without
recogn
airway
diseas
consequ
use
patient
underli
airway
diseas
gener
recom
mend
unit
state
although
treatment
atrisk
patient
use
countri
use
patient
obstruct
airway
diseas
zanamivir
administ
cautious
close
observ
avail
fastact
bronchodil
zanamivir
inhal
experiment
nebul
solut
contain
ing
mgml
minut
four
time
day
day
treatment
seriou
influenza
lower
respiratori
tract
sign
hospit
patient
year
older
well
toler
howev
oral
formul
contain
lactos
reformul
solut
administ
airway
mechan
ventil
lactos
precipit
airway
filter
caus
obstruct
preclud
reformul
powder
oral
inhal
formul
solut
nebul
inhal
zanamivir
inject
intraven
healthi
volunt
dose
mg
twice
daili
day
also
well
toler
hospit
adult
influenza
treat
zanamivir
mg
intraven
twice
daili
day
reduc
dose
renal
impair
safeti
signal
clinic
signific
trend
laboratori
valu
vital
sign
electrocardiogram
identifi
consid
attribut
drug
zanamivir
administ
patient
intranas
spray
oral
inhal
dri
powder
nasal
inhal
aerosol
nebul
solut
intraven
inject
intranas
intraven
zanamivir
highli
protect
experiment
human
influenza
earli
treatment
associ
reduct
viral
titer
symptom
middl
ear
pressur
abnor
maliti
oral
inhal
zanamivir
powder
approv
unit
state
prevent
influenza
individu
year
old
older
treatment
influenza
individu
year
old
older
zanamivir
mg
twice
daili
day
inhal
earli
cours
ill
treatment
uncompl
influenza
previous
healthi
adult
children
year
old
shorten
time
ill
resolut
return
usual
activ
day
treatment
benefit
seem
greater
patient
sever
symptom
entri
patient
older
year
higherrisk
patient
inhal
zanamivir
treatment
adult
associ
reduc
tion
lower
respiratori
tract
event
lead
antibiot
use
overal
reduct
antibiot
prescript
zanamivir
inhal
oral
equal
efficaci
treatment
influenza
b
infect
individu
influenza
b
ill
zanamivir
reduc
median
durat
fever
hour
hour
compar
oseltamivir
highrisk
patient
primarili
mild
moder
asthma
chronic
cardiopulmonari
condit
oral
inhal
zanamivir
treatment
reduc
ill
durat
incid
complic
lead
antibiot
use
use
treat
immunocompromis
host
influenza
b
infect
includ
child
aqueou
zanamivir
solu
tion
mgml
administ
aerosol
nebul
via
endotrach
tube
recent
observ
studi
oral
inhal
zanamivir
efficaci
treatment
oseltamivir
resist
influenza
oseltamivir
prophylact
administr
oncedaili
inhal
zanamivir
mg
prevent
febril
influenza
ill
influenza
season
efficaci
use
postexposur
prophylaxi
household
without
treatment
ill
index
case
efficaci
observ
studi
limit
number
patient
oral
inhal
zanamivir
oral
oseltamivir
differ
prevent
secondari
case
nosocomi
outbreak
pediatr
ward
nurs
home
resid
week
inhal
zanamivir
superior
oral
rimantadin
prevent
influenza
infect
part
high
frequenc
rimantadin
resist
inhal
zanamivir
oral
bioavail
zanamivir
low
approv
mulat
dri
powder
contain
lactos
carrier
deliv
oral
inhal
proprietari
diskhal
devic
proprietari
inhal
devic
deliv
zanamivir
breath
activ
requir
coop
er
train
patient
use
diskhal
devic
unreli
young
children
infirm
elderli
patient
cognit
impair
patient
although
inhal
use
effect
mani
older
adult
half
hospit
older
adult
could
correctli
use
devic
instruct
inhal
dri
powder
use
diskhal
approxi
mate
deposit
lower
respiratori
tract
remaind
deposit
oropharynx
zanamivir
concentr
epitheli
line
fluid
obtain
bronchoalveolar
lavag
may
approxim
concentr
alveoli
median
epitheli
line
fluid
concentr
zanamivir
hour
oral
inhal
rec
ommend
dose
diskhal
healthi
volunt
rang
uninfect
individu
median
zanamivir
level
induc
sputum
hour
hour
hour
dose
pulmonari
elim
estim
hour
approxim
inhal
dose
absorb
system
peak
plasma
level
low
averag
low
bioavail
zanamivir
inhal
oral
dosag
adjust
indic
renal
insuffici
intraven
dose
plasma
elim
zanamivir
rang
hour
elimin
unchang
urin
intraven
administr
mg
zanamivir
healthi
adult
median
serum
c
max
auc
hr
c
trough
median
epitheli
line
fluid
concentr
hour
dose
similar
valu
inhal
mg
see
earlier
time
vitro
ic
influenza
b
neuraminidas
respect
pharmacokinet
zanamivir
adult
influenza
receiv
mg
intraven
twice
daili
dose
adjust
renal
impair
similar
previous
describ
studi
zanamivir
renal
clearanc
declin
linearli
increas
renal
impair
suggest
dose
adult
normal
renal
function
mg
intraven
given
twice
daili
dose
children
patient
renal
impair
receiv
replac
therapi
publish
clinic
signific
drug
interact
recogn
inhal
zanamivir
clinic
relev
pharmacokinet
interact
demonstr
oseltamivir
mg
taken
oral
twice
daili
zanamivir
mg
administ
intraven
everi
hour
healthi
volunt
zanamivir
affect
immun
respons
inject
inactiv
influenza
vaccin
similar
antivir
medic
potenti
impair
immunogen
iti
attenu
live
influenza
vaccin
administ
concurr
zanamivir
administ
hour
week
intranas
administr
attenu
influenza
vaccin
toxic
preclin
studi
zanamivir
found
evid
mutagen
tera
togen
oncogen
effect
cell
cultur
inhibitori
effect
zanamivir
influenza
viru
replic
impair
analg
sic
antihistamin
decongest
antibacteri
drug
zanami
vir
classifi
pregnanc
categori
c
agent
oral
inhal
zanamivir
gener
well
toler
fre
quenci
complaint
significantli
differ
placebo
recipi
among
adult
children
year
old
older
includ
oncedaili
oral
inhal
prophylaxi
adult
week
report
symptom
treatment
studi
like
result
underli
ill
similarli
highrisk
patient
receiv
zanamivir
placebo
differ
advers
reaction
seen
control
trial
patient
mild
moder
asthma
chronic
obstruct
pulmonari
diseas
oral
inhal
zanamivir
associ
fewer
bronchiti
episod
similar
mea
surement
forc
expir
volum
second
rapid
pharmacokinet
specif
polymer
zanamivir
conju
gate
influenza
b
neuraminidas
presum
yet
report
zanamivir
polym
overcom
zanamivir
resist
zana
mivir
polym
bound
neuraminidas
zanamivirresist
avian
influenza
virus
possess
resist
mutat
posit
bound
much
time
strongli
monomer
zanamivir
synthesi
polymer
conjug
zanamivir
retain
neur
aminidas
inhibitori
activ
possibl
uniqu
posit
molecul
dock
enzymat
pocket
group
point
away
target
site
make
access
linkag
differ
backbon
molecul
electron
micro
graph
show
influenza
viru
clump
presenc
dimer
zana
mivir
conjug
mark
potenc
conjug
postul
reflect
clump
caus
three
type
bival
bind
two
neuraminidas
molecul
tetramer
transmembran
spike
protein
intratetram
bind
site
differ
tetram
virion
intravirion
headtohead
bind
differ
neuraminidas
site
separ
virion
intervirion
bind
addit
mechan
mark
enhanc
potenc
observ
synthesi
polymerattach
zanamivir
postul
result
interfer
intracellular
traffick
endoci
tose
viru
subsequ
virusendosom
fusion
studi
describ
attempt
induc
resist
vitro
repeat
passag
presenc
drug
report
prolong
retent
polymer
zanamivir
compar
mono
meric
zanamivir
lung
tissu
account
enhanc
antivir
effect
polymer
conjug
intratrach
instil
singl
dose
polymer
zanamivir
conjug
monomer
zanamivir
solut
rat
lung
homogen
drug
concentr
polymer
compound
hour
hour
time
time
greater
zanamivir
concentr
gener
lung
retent
time
directli
relat
molecular
weight
small
polar
molecul
leav
lung
pass
tight
junction
cell
prolong
retent
highmolecularweight
poli
meric
conjug
compar
monomer
zanamivir
expect
howev
prolong
lung
retent
time
smaller
conju
gate
indic
aqueou
insolubl
aggreg
format
plu
partit
cell
membran
phospholipid
may
also
play
role
prolong
retent
zanamivir
polymer
conjug
lung
inhal
toxic
studi
limit
assess
vitro
cyto
toxic
seri
dimer
conjug
concentr
ngml
caus
cytotox
clinic
studi
report
use
curtail
transmiss
amantadineresist
influ
enza
nurs
home
oral
inhal
zanamivir
administ
combin
oral
oseltamivir
postexposur
prophylaxi
famili
combin
zanamiviroseltamivir
administr
effica
ciou
either
agent
alon
howev
subgroup
analysi
suggest
greater
efficaci
combin
treatment
among
contact
whose
prophylaxi
begun
within
hour
exposur
index
case
compar
oseltamivir
zanamivir
alon
treatment
adult
mainli
influenza
zanamiviroseltamivir
combin
treatment
efficaci
zanamivir
alon
less
efficaci
oseltamivir
monotherapi
zanamivir
administ
intraven
treat
patient
serious
ill
influenza
could
receiv
fail
oral
oseltamivir
therapi
immunocompet
immunocompro
mise
patient
infect
oseltamivirresist
oseltamivirsuscept
influenza
nonpandem
virus
oseltamivirresist
pandem
viru
oseltamivir
sensit
influenza
viru
success
treat
intraven
zanamivir
sens
intraven
zanamivir
may
lifesav
howev
appar
lack
relat
ship
intraven
zanamivir
treatmentassoci
reduct
pandem
viru
load
upper
lower
respiratori
tract
secret
mortal
prompt
question
effect
seri
ousli
ill
patient
phase
iii
studi
compar
intraven
zanamivir
oseltamivir
hospit
patient
underway
polymer
zanamivir
conjug
experiment
highmolecular
weight
antiinfluenza
compound
compris
multipl
zanamivir
monom
connect
posit
backbon
linker
mol
ecul
variou
type
length
compound
poten
tial
secondgener
inhal
neuraminidas
inhibitor
influenza
chemoprophylaxi
therapi
enhanc
potenc
prolong
lung
retent
time
compar
zanamivir
mice
one
compound
associ
prophylact
efficaci
day
singl
intranas
administr
polymer
zanamivir
conjug
exhibit
broadspectrum
antiinfluenza
activ
inhibit
human
influenza
b
virus
avian
influenza
viru
inhibitori
potenc
vari
accord
length
type
linker
molecul
number
zana
mivir
deriv
whether
dimer
trimer
tetramer
potent
polymer
zanamivir
conjug
dimer
linker
less
potent
neuraminidas
assay
enzym
inhibit
test
ic
nm
vs
nm
zanamivir
fold
potent
inhibit
influenza
cyto
pathic
reduct
assay
ic
nm
vs
nm
zanamivir
mice
dimer
conjug
time
potent
zanamivir
prevent
influenza
viru
replic
lung
day
singl
intranas
dose
drug
day
intranas
viru
challeng
drug
dose
reduc
lung
viru
titer
mgkg
mgkg
dimer
conjug
zanamivir
prophylact
effect
associ
prolong
persist
dimer
conjug
lung
tissu
intranas
administr
discuss
section
complet
refer
list
avail
onlin
expert
consult
